Frank Yocca Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

Frank Yocca is Chief Scientific Officer of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 28,931 shares of BTAI, which is worth approximately $11,861. The most recent transaction as insider was on Dec 16, 2024, when has been sold 430 shares (Common Stock) at a price of $0.36 per share, resulting in proceeds of $154. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.9K

2.31% 3M change

161.61% 12M change

Total Value Held $11,861

Frank Yocca Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2024	SELL Open market or private sale	$154 $0.36 p/Share	430 Reduced 1.46%	28,931 Common Stock
Dec 15 2024	BUY Exercise of conversion of derivative security	-	562 Added 1.88%	29,361 Common Stock
Dec 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 1.78%	28,799 Common Stock
Oct 03 2024	SELL Open market or private sale	$3,946 $0.55 p/Share	7,175 Reduced 20.24%	28,278 Common Stock
Sep 17 2024	BUY Grant, award, or other acquisition	-	21,250 Added 37.48%	35,453 Common Stock
Sep 16 2024	SELL Open market or private sale	$244 $0.69 p/Share	355 Reduced 2.44%	14,203 Common Stock
Sep 15 2024	BUY Exercise of conversion of derivative security	-	563 Added 3.72%	14,558 Common Stock
Sep 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 3.59%	13,995 Common Stock
Jun 17 2024	SELL Open market or private sale	$476 $1.28 p/Share	372 Reduced 2.69%	13,474 Common Stock
Jun 15 2024	BUY Exercise of conversion of derivative security	-	562 Added 3.9%	13,846 Common Stock
Jun 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 3.77%	13,284 Common Stock
Apr 04 2024	SELL Open market or private sale	$2,806 $2.63 p/Share	1,067 Reduced 7.72%	12,763 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	-	2,250 Added 13.99%	13,830 Common Stock
Mar 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 4.31%	11,580 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 4.5%	11,059 Common Stock
Sep 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 4.71%	10,538 Common Stock
Jun 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 4.94%	10,017 Common Stock
Mar 15 2023	SELL Open market or private sale	$19,394 $19.69 p/Share	985 Reduced 9.4%	9,496 Common Stock
Mar 14 2023	BUY Exercise of conversion of derivative security	-	2,084 Added 16.59%	10,481 Common Stock
Jan 20 2023	SELL Open market or private sale	$1,500,000 $30.0 p/Share	50,000 Reduced 85.62%	8,397 Common Stock
Mar 15 2021	SELL Open market or private sale	$733,350 $48.89 p/Share	15,000 Reduced 20.44%	58,397 Common Stock
Feb 16 2021	SELL Open market or private sale	$877,950 $58.53 p/Share	15,000 Reduced 16.97%	73,397 Common Stock
Jan 25 2021	SELL Open market or private sale	$721,050 $48.07 p/Share	15,000 Reduced 14.51%	88,397 Common Stock
Jan 25 2021	BUY Exercise of conversion of derivative security	$6,150 $0.41 p/Share	15,000 Added 12.67%	103,397 Common Stock

Frank Yocca

Chief Scientific Officer

New Haven, CT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTAI shares.

Notify only if

Value

Insider Trading

Get notified when an Bio Xcel Therapeutics, Inc. insider buys or sells BTAI shares.

Notify only if

Operation

Value

Type

News

Receive news related to BioXcel Therapeutics, Inc.

Track Activities on BTAI

Account